<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB02031</drugbank-id>
  <drugbank-id>EXPT03050</drugbank-id>
  <name>(6S)-5,6,7,8-tetrahydrofolic acid</name>
  <description/>
  <cas-number>135-16-0</cas-number>
  <unii/>
  <average-mass>445.4292</average-mass>
  <monoisotopic-mass>445.170981503</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>experimental</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication/>
  <pharmacodynamics/>
  <mechanism-of-action/>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as tetrahydrofolic acids. These are heterocyclic compounds based on the 5,6,7,8-tetrahydropteroic acid skeleton conjugated with at least one L-glutamic acid unit.</description>
    <direct-parent>Tetrahydrofolic acids</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organoheterocyclic compounds</superclass>
    <class>Pteridines and derivatives</class>
    <subclass>Pterins and derivatives</subclass>
    <alternative-parent>Amino acids</alternative-parent>
    <alternative-parent>Aminobenzamides</alternative-parent>
    <alternative-parent>Aminopyrimidines and derivatives</alternative-parent>
    <alternative-parent>Aniline and substituted anilines</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Benzoyl derivatives</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Carboxylic acids</alternative-parent>
    <alternative-parent>Dicarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Glutamic acid and derivatives</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hippuric acids</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>N-acyl-alpha amino acids</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Phenylalkylamines</alternative-parent>
    <alternative-parent>Primary amines</alternative-parent>
    <alternative-parent>Pyrimidones</alternative-parent>
    <alternative-parent>Secondary alkylarylamines</alternative-parent>
    <alternative-parent>Secondary carboxylic acid amides</alternative-parent>
    <alternative-parent>Vinylogous amides</alternative-parent>
    <substituent>Alpha-amino acid or derivatives</substituent>
    <substituent>Amine</substituent>
    <substituent>Amino acid</substituent>
    <substituent>Amino acid or derivatives</substituent>
    <substituent>Aminobenzamide</substituent>
    <substituent>Aminobenzoic acid or derivatives</substituent>
    <substituent>Aminopyrimidine</substituent>
    <substituent>Aniline or substituted anilines</substituent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Benzamide</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Benzoic acid or derivatives</substituent>
    <substituent>Benzoyl</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxamide group</substituent>
    <substituent>Carboxylic acid</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Dicarboxylic acid or derivatives</substituent>
    <substituent>Glutamic acid or derivatives</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hippuric acid</substituent>
    <substituent>Hippuric acid or derivatives</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>N-acyl-alpha amino acid or derivatives</substituent>
    <substituent>N-acyl-alpha-amino acid</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Phenylalkylamine</substituent>
    <substituent>Primary amine</substituent>
    <substituent>Pyrimidine</substituent>
    <substituent>Pyrimidone</substituent>
    <substituent>Secondary aliphatic/aromatic amine</substituent>
    <substituent>Secondary amine</substituent>
    <substituent>Secondary carboxylic acid amide</substituent>
    <substituent>Tetrahydrofolic acid</substituent>
    <substituent>Vinylogous amide</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">(6S)-5,6,7,8-tetrahydrofolate</synonym>
    <synonym language="english" coder="">(6S)-5,6,7,8-tetrahydropteroylglutamate</synonym>
    <synonym language="english" coder="">(6S)-H4folate</synonym>
    <synonym language="english" coder="">(6S)-tetrahydrofolate</synonym>
    <synonym language="english" coder="">(6S)-Tetrahydrofolic acid</synonym>
    <synonym language="english" coder="">(6S)-THFA</synonym>
  </synonyms>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Folic Acid and Derivatives</category>
      <mesh-id/>
    </category>
    <category>
      <category>Vitamin B Complex</category>
      <mesh-id>D014803</mesh-id>
    </category>
    <category>
      <category>Vitamins</category>
      <mesh-id>D014815</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>1kzi</pdb-entry>
    <pdb-entry>1m7v</pdb-entry>
    <pdb-entry>1m7z</pdb-entry>
    <pdb-entry>1u22</pdb-entry>
    <pdb-entry>1woo</pdb-entry>
    <pdb-entry>2yck</pdb-entry>
    <pdb-entry>3bhl</pdb-entry>
    <pdb-entry>3bhr</pdb-entry>
    <pdb-entry>3g5r</pdb-entry>
    <pdb-entry>3gsi</pdb-entry>
    <pdb-entry>3tfj</pdb-entry>
    <pdb-entry>4ccz</pdb-entry>
    <pdb-entry>4kum</pdb-entry>
    <pdb-entry>4o1f</pdb-entry>
    <pdb-entry>4paa</pdb-entry>
    <pdb-entry>4pab</pdb-entry>
    <pdb-entry>4qpd</pdb-entry>
    <pdb-entry>5t7o</pdb-entry>
    <pdb-entry>5x1l</pdb-entry>
    <pdb-entry>5x1m</pdb-entry>
    <pdb-entry>5x1n</pdb-entry>
    <pdb-entry>6a9a</pdb-entry>
    <pdb-entry>6cw7</pdb-entry>
    <pdb-entry>6j1f</pdb-entry>
    <pdb-entry>6j1j</pdb-entry>
    <pdb-entry>6mr9</pdb-entry>
    <pdb-entry>6mt8</pdb-entry>
    <pdb-entry>6mth</pdb-entry>
  </pdb-entries>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB01320</drugbank-id>
      <name>Fosphenytoin</name>
      <description>The serum concentration of Fosphenytoin can be decreased when it is combined with (6S)-5,6,7,8-tetrahydrofolic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00293</drugbank-id>
      <name>Raltitrexed</name>
      <description>The therapeutic efficacy of Raltitrexed can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>The serum concentration of (6S)-5,6,7,8-tetrahydrofolic acid can be decreased when it is combined with Sulfasalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00252</drugbank-id>
      <name>Phenytoin</name>
      <description>The serum concentration of Phenytoin can be decreased when it is combined with (6S)-5,6,7,8-tetrahydrofolic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08898</drugbank-id>
      <name>Glucarpidase</name>
      <description>The serum concentration of the active metabolites of (6S)-5,6,7,8-tetrahydrofolic acid can be reduced when (6S)-5,6,7,8-tetrahydrofolic acid is used in combination with Glucarpidase resulting in a loss in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>The serum concentration of Phenobarbital can be decreased when it is combined with (6S)-5,6,7,8-tetrahydrofolic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00794</drugbank-id>
      <name>Primidone</name>
      <description>The serum concentration of Primidone can be decreased when it is combined with (6S)-5,6,7,8-tetrahydrofolic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00205</drugbank-id>
      <name>Pyrimethamine</name>
      <description>The therapeutic efficacy of Pyrimethamine can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00250</drugbank-id>
      <name>Dapsone</name>
      <description>The therapeutic efficacy of Dapsone can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00440</drugbank-id>
      <name>Trimethoprim</name>
      <description>The therapeutic efficacy of Trimethoprim can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>The therapeutic efficacy of Methotrexate can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00642</drugbank-id>
      <name>Pemetrexed</name>
      <description>The therapeutic efficacy of Pemetrexed can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01131</drugbank-id>
      <name>Proguanil</name>
      <description>The therapeutic efficacy of Proguanil can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01157</drugbank-id>
      <name>Trimetrexate</name>
      <description>The therapeutic efficacy of Trimetrexate can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03695</drugbank-id>
      <name>Piritrexim</name>
      <description>The therapeutic efficacy of Piritrexim can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04655</drugbank-id>
      <name>Metoprine</name>
      <description>The therapeutic efficacy of Metoprine can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06358</drugbank-id>
      <name>Iclaprim</name>
      <description>The therapeutic efficacy of Iclaprim can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06813</drugbank-id>
      <name>Pralatrexate</name>
      <description>The therapeutic efficacy of Pralatrexate can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08878</drugbank-id>
      <name>Aminopterin</name>
      <description>The therapeutic efficacy of Aminopterin can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12769</drugbank-id>
      <name>Lometrexol</name>
      <description>The therapeutic efficacy of Lometrexol can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12912</drugbank-id>
      <name>Nolatrexed</name>
      <description>The therapeutic efficacy of Nolatrexed can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13795</drugbank-id>
      <name>Brodimoprim</name>
      <description>The therapeutic efficacy of Brodimoprim can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14763</drugbank-id>
      <name>Cycloguanil</name>
      <description>The therapeutic efficacy of Cycloguanil can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00375</drugbank-id>
      <name>Colestipol</name>
      <description>The serum concentration of (6S)-5,6,7,8-tetrahydrofolic acid can be decreased when it is combined with Colestipol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00544</drugbank-id>
      <name>Fluorouracil</name>
      <description>The risk or severity of adverse effects can be increased when (6S)-5,6,7,8-tetrahydrofolic acid is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01099</drugbank-id>
      <name>Flucytosine</name>
      <description>The risk or severity of adverse effects can be increased when (6S)-5,6,7,8-tetrahydrofolic acid is combined with Flucytosine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01101</drugbank-id>
      <name>Capecitabine</name>
      <description>The risk or severity of adverse effects can be increased when (6S)-5,6,7,8-tetrahydrofolic acid is combined with Capecitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01629</drugbank-id>
      <name>5-fluorouridine</name>
      <description>The risk or severity of adverse effects can be increased when (6S)-5,6,7,8-tetrahydrofolic acid is combined with 5-fluorouridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03419</drugbank-id>
      <name>Uracil</name>
      <description>The risk or severity of adverse effects can be increased when (6S)-5,6,7,8-tetrahydrofolic acid is combined with Uracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09256</drugbank-id>
      <name>Tegafur</name>
      <description>The risk or severity of adverse effects can be increased when (6S)-5,6,7,8-tetrahydrofolic acid is combined with Tegafur.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12947</drugbank-id>
      <name>Doxifluridine</name>
      <description>The risk or severity of adverse effects can be increased when (6S)-5,6,7,8-tetrahydrofolic acid is combined with Doxifluridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00313</drugbank-id>
      <name>Valproic acid</name>
      <description>The serum concentration of (6S)-5,6,7,8-tetrahydrofolic acid can be decreased when it is combined with Valproic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>The serum concentration of Carbamazepine can be decreased when it is combined with (6S)-5,6,7,8-tetrahydrofolic acid.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-1.5</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-3.2</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>2.88e-01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-1.9</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(2S)-2-{[4-({[(6S)-2-amino-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]formamido}pentanedioic acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>tetrahydropteroylglutamic acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>445.4292</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>445.170981503</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>NC1=NC2=C(N[C@@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CN2)C(=O)N1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C19H23N7O6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C19H23N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,11-12,21,23H,5-8H2,(H,24,29)(H,27,28)(H,31,32)(H4,20,22,25,26,30)/t11-,12-/m0/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>MSTNYGQPCMXVAQ-RYUDHWBXSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>207.27</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>121.59</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>44.46</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>9</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>11</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>8</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>3.46</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>2.78</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>15635</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>5460413</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46508587</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>4573946</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>THG</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0001433</id>
      <name>Nitric oxide synthase oxygenase</name>
      <organism>Bacillus subtilis (strain 168)</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O34453" source="Swiss-Prot">
        <name>Nitric oxide synthase oxygenase</name>
        <general-function>Nitric-oxide synthase activity</general-function>
        <specific-function>Catalyzes the production of nitric oxide.</specific-function>
        <gene-name>nos</gene-name>
        <locus/>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>5.78</theoretical-pi>
        <molecular-weight>41902.9</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="224308">Bacillus subtilis (strain 168)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>D86417</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>2443234</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O34453</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>NOSO_BACSU</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.13.165</synonym>
          <synonym>NOSoxy-like protein</synonym>
          <synonym>yflM</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037142|Nitric oxide synthase oxygenase
MEEKEILWNEAKAFIAACYQELGKEEEVKDRLADIKSEIDLTGSYVHTKEELEHGAKMAW
RNSNRCIGRLFWNSLNVIDRRDVRTKEEVRDALFHHIETATNNGKIRPTITIFPPEEKGE
KQVEIWNHQLIRYAGYESDGERIGDPASCSLTAACEELGWRGERTDFDLLPLIFRMKGDE
QPVWYELPRSLVIEVPITHPDIEAFSDLELKWYGVPIISDMKLEVGGIHYNAAPFNGWYM
GTEIGARNLADEKRYDKLKKVASVIGIAADYNTDLWKDQALVELNKAVLHSYKKQGVSIV
DHHTAASQFKRFEEQEEEAGRKLTGDWTWLIPPISPAATHIFHRSYDNSIVKPNYFYQDK
PYE</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016423|Nitric oxide synthase oxygenase (nos)
TTGGAAGAAAAAGAAATACTCTGGAACGAAGCGAAAGCGTTTATTGCCGCATGCTATCAG
GAATTGGGAAAGGAGGAGGAAGTGAAAGACCGTCTCGCGGACATTAAAAGTGAAATTGAC
CTGACCGGAAGCTATGTACATACGAAGGAAGAGCTGGAGCACGGAGCGAAAATGGCTTGG
AGAAACAGCAACCGCTGCATCGGCAGATTGTTCTGGAATTCGCTGAATGTTATCGACAGA
CGAGACGTCCGGACGAAGGAGGAAGTGCGTGATGCCCTCTTTCACCATATTGAAACCGCC
ACCAATAACGGGAAAATCAGACCGACCATTACGATTTTCCCTCCGGAAGAGAAGGGTGAA
AAGCAAGTCGAGATCTGGAATCATCAGCTGATCCGGTACGCTGGATATGAGTCAGACGGA
GAAAGAATCGGCGACCCGGCTTCCTGTTCCCTGACAGCAGCCTGCGAAGAGCTCGGCTGG
CGCGGAGAGCGAACGGATTTTGACCTGCTGCCGCTCATTTTTCGCATGAAAGGGGACGAG
CAGCCTGTCTGGTATGAGCTGCCGCGTTCACTTGTGATTGAGGTTCCAATCACACATCCG
GACATCGAGGCGTTTTCTGATTTGGAGCTGAAGTGGTACGGCGTGCCTATTATTTCTGAT
ATGAAGCTTGAGGTCGGGGGCATTCATTATAATGCCGCGCCATTTAACGGCTGGTATATG
GGCACGGAGATCGGAGCGAGAAACCTCGCAGATGAAAAGCGGTACGACAAGCTCAAAAAA
GTAGCGTCCGTGATCGGCATCGCCGCTGATTACAATACGGATTTATGGAAGGATCAAGCG
CTAGTTGAATTGAATAAAGCTGTGCTGCACTCGTATAAAAAGCAGGGTGTCAGCATCGTT
GACCATCATACAGCGGCAAGCCAGTTTAAACGGTTTGAAGAACAGGAGGAAGAAGCGGGC
AGAAAGCTGACGGGGGACTGGACGTGGCTGATTCCGCCAATTTCACCCGCTGCCACTCAT
ATCTTCCACCGCTCCTATGATAACTCAATCGTTAAGCCGAACTATTTTTATCAAGATAAG
CCTTATGAGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02898</identifier>
            <name>NO_synthase</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>nitric-oxide synthase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nitric oxide biosynthetic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target>
      <id>BE0001438</id>
      <name>Thymidylate synthase</name>
      <organism>Escherichia coli (strain K12)</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P0A884" source="Swiss-Prot">
        <name>Thymidylate synthase</name>
        <general-function>Thymidylate synthase activity</general-function>
        <specific-function>Provides the sole de novo source of dTMP for DNA biosynthesis. This protein also binds to its mRNA thus repressing its own translation.</specific-function>
        <gene-name>thyA</gene-name>
        <locus/>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>5.94</theoretical-pi>
        <molecular-weight>30479.475</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="83333">Escherichia coli (strain K12)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J01710</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>147987</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P0A884</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>TYSY_ECOLI</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.1.1.45</synonym>
          <synonym>TS</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0011008|Thymidylate synthase
MKQYLELMQKVLDEGTQKNDRTGTGTLSIFGHQMRFNLQDGFPLVTTKRCHLRSIIHELL
WFLQGDTNIAYLHENNVTIWDEWADENGDLGPVYGKQWRAWPTPDGRHIDQITTVLNQLK
NDPDSRRIIVSAWNVGELDKMALAPCHAFFQFYVADGKLSCQLYQRSCDVFLGLPFNIAS
YALLVHMMAQQCDLEVGDFVWTGGDTHLYSNHMDQTHLQLSREPRPLPKLIIKRKPESIF
DYRFEDFEIEGYDPHPGIKAPVAI</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0011009|Thymidylate synthase (thyA)
ATGAAACAGTATTTAGAACTGATGCAAAAAGTGCTCGACGAAGGCACACAGAAAAACGAC
CGTACCGGAACCGGAACGCTTTCCATTTTTGGTCATCAGATGCGTTTTAACCTGCAAGAT
GGATTCCCGCTGGTGACAACTAAACGTTGCCACCTGCGTTCCATCATCCATGAACTGCTG
TGGTTTCTGCAGGGCGACACTAACATTGCTTATCTACACGAAAACAATGTCACCATCTGG
GACGAATGGGCCGATGAAAACGGCGACCTCGGGCCAGTGTATGGTAAACAGTGGCGCGCC
TGGCCAACGCCAGATGGTCGTCATATTGACCAGATCACTACGGTACTGAACCAGCTGAAA
AACGACCCGGATTCGCGCCGCATTATTGTTTCAGCGTGGAACGTAGGCGAACTGGATAAA
ATGGCGCTGGCACCGTGCCATGCATTCTTCCAGTTCTATGTGGCAGACGGCAAACTCTCT
TGCCAGCTTTATCAGCGCTCCTGTGACGTCTTCCTCGGCCTGCCGTTCAACATTGCCAGC
TACGCGTTATTGGTGCATATGATGGCGCAGCAGTGCGATCTGGAAGTGGGTGATTTTGTC
TGGACCGGTGGCGACACGCATCTGTACAGCAACCATATGGATCAAACTCATCTGCAATTA
AGCCGCGAACCGCGTCCGCTGCCGAAGTTGATTATCAAACGTAAACCCGAATCCATCTTC
GACTACCGTTTCGAAGACTTTGAGATTGAAGGCTACGATCCGCATCCGGGCATTAAAGCG
CCGGTGGCTATCTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00303</identifier>
            <name>Thymidylat_synt</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>thymidylate synthase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dTMP biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dTTP biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of translation</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>